Die Information für Ärzte und Apotheker
Neutral, unabhängig und anzeigenfrei
arznei-telegramm® 07/2019
previous issue next issue
This is a translation of the table of contents. One article is translated and freely available.

NEW ON THE MARKET
Dapagliflozin (FORXIGA): first oral antidiabetic for type 1 diabetes
Risankizumab (SKYRIZI) for psoriasis

THERAPY FROM A CRITICAL VIEWPOINT
COMPASS trial: pantoprazole safe, but without benefit

a-t READERS QUESTIONS AND COMMENTS
High dose statin for coronary heart disease?
Methotrexate (LANTAREL, generics) for rheumatoid arthritis or psoriasis prefer subcutaneous over oral application?

IN BRIEF
Platelet aggregation inhibitors after cerebral haemorrhage yes or no?

CURRENT ADR NETWORK REPORT
Generalized pruritus due to empagliflozin (JARDIANCE)  free article 

SIDE EFFECTS
Caution: increased mortality with the gout medication febuxostat (ADENURIC)
EMA: long-lasting sexual adverse effects due to SSRI and SNRI

e a-t ON THE INTERNET
Risankizumab (SKYRIZI) for psoriasis (long version)
Tocilizumab (ROACTEMRA): severe liver damage
EMA: long-lasting sexual adverse effects due to SSRI and SNRI (long version)
© 2019 arznei-telegramm